ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes

Abstract Background Venetoclax (VEN) in combination with hypomethylating agents has emerged as a pivotal therapy for elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, monocytic AML exhibit greater resistance to VEN-based regimens compared to non-monocytic...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Lei Zhao, Xinrong Xiang, Ailing Zhong, Hongbin Yu, Jinjun Yang, Mengran Chen, Hong Ding, Chenlu Yang, Yu Wu
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2025-11-01
סדרה:	BMC Cancer
נושאים:	Sphingolipid Acute myeloid leukemia Venetoclax Drug resistance Monocytic
גישה מקוונת:	https://doi.org/10.1186/s12885-025-15272-9
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!